Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

BACKGROUND: The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding cetuximab to FOLFOX or FOLFIRI increased efficacy in patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Folprecht, Gunnar, Hamann, Susanne, Schütte, Katharina, Trarbach, Tanja, Stoehlmacher-Williams, Jan, Ehninger, Gerhard
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223588/
https://ncbi.nlm.nih.gov/pubmed/25038824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-521
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky